Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
40.9 HKD | -2.27% | +13.14% | -4.33% |
Apr. 30 | Innovent Biologics, Inc. Reports Revenue Results for the First Quarter of 2024 | CI |
Apr. 30 | Innovent Biologics, Inc. Appoints Samuel Zhang as Global Chief Business Officer | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Sales forecast by analysts have been recently revised upwards.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-4.33% | 8.69B | B- | ||
-3.79% | 87.06B | A- | ||
+2.76% | 40.25B | A- | ||
-17.49% | 31.09B | B- | ||
+54.18% | 24.74B | A | ||
-13.13% | 15.91B | C | ||
-9.12% | 11.96B | D+ | ||
-15.45% | 11.92B | B- | ||
-42.56% | 11.61B | B | ||
+5.77% | 8.73B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 1801 Stock
- Ratings Innovent Biologics, Inc.